News headlines about Ultragenyx Pharmaceutical (NASDAQ:RARE) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ultragenyx Pharmaceutical earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.3360668813349 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s analysis:
- Ultragenyx Pharmaceutical (RARE) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Zacks: Brokerages Expect Ultragenyx Pharmaceutical Inc (RARE) Will Post Quarterly Sales of $59.13 Million (americanbankingnews.com)
- Ultragenyx Pharmaceutical (RARE) Upgraded by Evercore ISI to “Outperform” (americanbankingnews.com)
- Zacks: Analysts Expect Ultragenyx Pharmaceutical Inc (RARE) Will Post Earnings of -$0.91 Per Share (americanbankingnews.com)
Shares of Ultragenyx Pharmaceutical stock opened at $50.99 on Friday. The company has a market capitalization of $2,529.41, a price-to-earnings ratio of -6.80 and a beta of 1.93. Ultragenyx Pharmaceutical has a 52 week low of $41.67 and a 52 week high of $71.99.
Several brokerages recently weighed in on RARE. BidaskClub cut shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, February 9th. Zacks Investment Research cut shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Credit Suisse Group began coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 17th. They issued an “outperform” rating and a $67.00 target price on the stock. Morgan Stanley reaffirmed an “equal weight” rating and issued a $60.00 target price (up previously from $57.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 21st. Finally, Jefferies Group raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and raised their target price for the company from $58.00 to $72.00 in a report on Monday, December 4th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $68.76.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.